{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/6311fe9bae5d13001250521f/690d8e3cc1ed8717c5a569e0?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Your crashcourse in biotech commercialisation Part 1 - key considerations on the core science and adjacent considerations to take your drug to market- STEM essentials","description":"<p>You’ve got strong data and maybe even a first-in-class idea, but do you know what it <em>really</em> takes to get your molecule from the bench to the bedside?</p><p><br></p><p>🔍 <strong>What You’ll Learn:</strong></p><p> If you’re a STEM researcher, biotech founder, or academic thinking about commercialising your work, this episode breaks down the unseen steps between great science and a viable medicine.</p><p>You’ll learn:</p><p> • Why promising discoveries often fail — and how to spot the strategic blind spots early.</p><p> • How to define your <em>target product profile</em> and use it to align experiments, reduce risk, and attract funding.</p><p> • The “adjacent” essentials that make or break translation: IP timing, manufacturing readiness, and regulatory strategy.</p><p>🎯 Hit play to learn what investors, regulators, and industry partners really want to see before backing your science.</p><p><br></p><p>🧠 <strong>About the Guests:</strong></p><p> This episode features insights from the 2025 ARCS Drug Discovery Forum, where early-stage researchers pitched their projects to a panel of industry veterans and investors.</p><p> You’ll hear from:</p><ul><li><strong>Tim Boyle</strong>, CEO of ARCS Australia, on why upskilling and connection across the ecosystem are critical for success.</li><li><strong>Dr Wolfgang Jarolimek</strong>, Head of Drug Discovery at Syntara, on the importance of early pharmacokinetics and target engagement.</li><li><strong>Mike Lamprecht</strong>, Investment Manager at Tenmile, on designing “fail fast” experiments that protect capital and credibility.</li><li><strong>Dr Pegah Varamini</strong>, University of Sydney, and <strong>Dr Daniel Beard</strong>, University of Newcastle, on the real-life questions and lessons from taking lab discoveries closer to market.</li></ul><p><br></p><p>📌 <strong>Episode Highlights:</strong></p><p> 00:00 From promising data to the maze of translation</p><p> 02:15 Tim Boyle on why ARCS bridges research and industry</p><p> 05:00 Why there’s no one-size-fits-all roadmap</p><p> 08:00 Why “good science” isn’t enough for commercial success</p><p> 10:00 The Target Product Profile — your map from lab to market</p><p> 12:30 The art of “fail fast” and defining go/no-go experiments</p><p> 13:45 The non-negotiables: pharmacokinetics and target engagement</p><p> 16:00 When $500M fails: the Simtuzumab story</p><p> 18:00 How Pegah Varamini prepared for investor questions</p><p> 21:00 The GMP vs non-GMP debate — what founders should know</p><p> 23:00 Parallel priorities: IP, formulation, and manufacturing</p><p> 24:00 Key takeaways and what’s next in the series</p><p><br></p><p>🤔 <strong>Reflection Time:</strong></p><ol><li>If you had to define your <em>Target Product Profile</em> today, what would your “no-go” experiment look like?</li><li>Which adjacent area — IP, manufacturing, or regulatory — could derail your science if ignored too long?</li><li>Who do you need in your circle to ask the right questions <em>before</em> it’s too late?</li></ol><p><br></p><p>♻️ share this episode with researcher and biotechs scientists. </p><p><br></p>","author_name":"Angelique Greco | Biotech & Health-Tech Expert | STEM Thought Leadership Coach"}